Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.
Presentation & Investor Materials
May 12, 2023
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Recent News Releases
Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023
Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
There are currently no events scheduled.